

**TORRENT PHARMACEUTICALS LIMITED**

**AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED AND NINE MONTHS ENDED ON 31ST DECEMBER 2009**

[Rs. in Lacs except per share data]

PARTICULARS	QUARTER ENDED		NINE MONTH ENDED		YEAR ENDED
	31-Dec-09	31-Dec-08	31-Dec-09	31-Dec-08	31-Mar-09
Sales [see note 2]	34224	30463	104730	86843	114827
Less: Excise Duty collected	65	115	218	320	382
Net Sales	34159	30348	104512	86523	114445
Other Operating Income	1434	1723	4634	3016	4044
<b>Total Income</b>	<b>35593</b>	<b>32071</b>	<b>109146</b>	<b>89539</b>	<b>118489</b>
<b>Expenditure</b>					
(Increase) / Decrease in Stock in Trade	(1247)	(164)	437	(34)	(1150)
Consumption of Raw / Packing Materials	10637	9243	30784	27382	37696
Purchase of Traded Goods	1972	1323	4122	3812	5429
Employees Cost	4016	3245	11882	9860	13299
Research and Development Expenses	2459	2346	8300	7512	10582
Depreciation and Amortisation	1101	945	3173	2634	3739
Other Expenditure	7696	8289	21870	20788	27293
<b>Total Expenditure</b>	<b>26634</b>	<b>25227</b>	<b>80568</b>	<b>71954</b>	<b>96888</b>
<b>Profit from Operations before Other Income, Interest and Exceptional Items</b>	<b>8959</b>	<b>6844</b>	<b>28578</b>	<b>17585</b>	<b>21601</b>
Other Income	231	235	509	520	336
<b>Profit before Interest and Exceptional Items</b>	<b>9190</b>	<b>7079</b>	<b>29087</b>	<b>18105</b>	<b>21937</b>
Net Borrowing Costs	301	388	1208	1519	1944
<b>Profit after Interest but before Exceptional Items</b>	<b>8889</b>	<b>6691</b>	<b>27879</b>	<b>16586</b>	<b>19993</b>
Exceptional Items [see note 3]	(1400)	(875)	(1400)	(875)	(876)
<b>Profit from Ordinary Activities before tax</b>	<b>7489</b>	<b>5816</b>	<b>26479</b>	<b>15711</b>	<b>19117</b>
Tax Expense [see note 4]	1167	217	10212	533	444
<b>Net Profit from Ordinary Activities after tax</b>	<b>6322</b>	<b>5599</b>	<b>16267</b>	<b>15178</b>	<b>18673</b>
Paid-up Equity Share Capital (Face Value of Rs.5)	4231	4231	4231	4231	4231
Reserves excluding Revaluation Reserves	-	-	-	-	69037
Basic and Diluted EPS for the period	7.47	6.62	19.23	17.94	22.07
Public shareholding					
Number of shares	24109500	24109500	24109500	24109500	24109500
Percentage of shareholding	28.49%	28.49%	28.49%	28.49%	28.49%
Promoters and promoter group Shareholding					
(a) Pledged/Encumbered					
- Number of shares	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
(b) Non-encumbered					
- Number of shares	60501860	60501860	60501860	60501860	60501860
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	71.51%	71.51%	71.51%	71.51%	71.51%

**Notes :**

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 27-Jan-10. There is no qualification in the Auditors Report on this statement of financial results.
- 2 The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Particulars	Quarter Ended			Nine Months Ended			Rs. in Lacs
	31-Dec-09	31-Dec-08	Growth %	31-Dec-09	31-Dec-08	Growth %	Year Ended 31-Mar-09
Domestic Formulations	18298	15976	15%	56291	48957	15%	62818
Exports	11562	9955	16%	34085	25816	32%	35470
Contract Manufacture	4316	4510	(4%)	14202	11940	19%	16385
Others	48	22	-	152	130	-	154
<b>Gross Sales</b>	<b>34224</b>	<b>30463</b>	<b>12%</b>	<b>104730</b>	<b>86843</b>	<b>21%</b>	<b>114827</b>
Less : Excise duty	65	115	-	218	320	-	382
<b>Net Sales</b>	<b>34159</b>	<b>30348</b>	<b>13%</b>	<b>104512</b>	<b>86523</b>	<b>21%</b>	<b>114445</b>

- 3 Exceptional item for the current quarter represents amount provided for impairment of loan given to Zao Torrent Pharma, a wholly owned subsidiary in Russia.
- 4 (a) During the first quarter of the current financial year "MAT credit entitlement asset" of Rs 5286 lacs recognised in earlier years, was written-off based on amendments made in Income Tax Act 1961, and other relevant factors, and in terms of the "Guidance Note on Accounting for Credit Available in respect of MAT under the Income-tax Act, 1961" issued by the Institute of Chartered Accountants of India.  
  
(b) The Company has not recognised "MAT credit entitlement asset" in the current quarter and period ended on 31-Dec-09. The comparative quarter and period ended on 31-Dec-08 includes such credit of Rs 564 lacs and Rs 1589 lacs respectively.
- 5 During the quarter, "Torrent Pharma Canada Inc.", a wholly owned subsidiary, has been incorporated in Canada on 25-Nov-09.
- 6 Status of investor complaints : Pending as of 01-Oct-09 - 1, received during the quarter - nil, disposed off during the quarter - 1, pending as of 31-Dec-09 - nil.
- 7 The Company has also prepared and published unaudited consolidated financial results for the quarter and nine months ended, which were subjected to limited review by the statutory auditors of the Company.

For TORRENT PHARMACEUTICALS LIMITED

Place : Ahmedabad  
Date : 27-Jan-10

sd/-  
SUDHIR MEHTA  
Chairman

.... Visit us at [www.torrentpharma.com](http://www.torrentpharma.com)....